Hansen Kosasih

Children's Cancer Institute Australia

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Immunology Immunology professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (13)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

Alicia Oshlack

Program Head

Peter MacCallum Cancer Centre

AUSTRALIA

View details

Russell Pickford

UNSW Sydney

AUSTRALIA

View details

Teresa Sadras

Laboratory Head

Olivia Newton-John Cancer Research Institute

AUSTRALIA

View details

Marc Mansour

Professor

University College London

UNITED KINGDOM

View details

Christopher Smith

Children's Cancer Institute Australia

AUSTRALIA

View details

Richard Lock

Head

Children's Cancer Institute Australia

AUSTRALIA

View details

Steven Goossens

Professor at Ghent University

Ghent University

BELGIUM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hansen Kosasih

Research Interests

Explore related searches

Contact this professor

Articles (13)

Cell surface surprise: NPM1 is an immune therapy target for acute myeloid leukemia

In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts

Less is more: Depleting myeloid‐biased HSCs to restore immune function

In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts

A novel MYB::PAIP1 oncogenic fusion in pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN) is dependent on BCL2 expression and is sensitive to venetoclax

A novel MYB::PAIP1 oncogenic fusion in pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN) is dependent on BCL2 expression and is sensitive to venetoclax

Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma

PU.1 eviction at lymphocyte-specific chromatin domains mediates glucocorticoid response in acute lymphoblastic leukemia

The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia

Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma.

TALLSorts: a T-cell acute lymphoblastic leukemia subtype classifier using RNA-seq expression data

TALLSorts: a T-cell acute lymphoblastic leukemia subtype classifier using RNA-seq expression data

The AKR1C3-Activated Prodrug, Achm-025, Eradicates Disease in Preclinical Models of Aggressive T-Cell Acute Lymphoblastic Leukemia

Collaborators (7)

Alicia Oshlack

Russell Pickford

Teresa Sadras

Marc Mansour

Christopher Smith

Richard Lock

Steven Goossens

Make your next move.